Drug profile

The FDA adverse-event record for Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus

443 FDA reports name Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#330 of 2,679
by report volume (all drugs)
443
adverse-event reports
9.5%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus ranks #330 of 2679 by total reports (443) and #566 of 1130 by death-coded share (9.5%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#330
This drug, reports of 2679
#566
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus has 443 reports now versus 443 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus changes

Signature read: 443 reports place Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus in the upper third of FDA AER volume (#330 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
443
Total Reports
42
Deaths Reported
9.5%
Death-coded share of reports

Active Ingredients

Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus

Administration Routes

SubcutaneousParenteralUnknownOralOtherSubconjunctival

Species Affected

Dog 443

Most Affected Breeds

Retriever - Labrador 49
Retriever - Golden 39
Chihuahua 25
Shih Tzu 22
Shepherd Dog - Australian 22
Dachshund (unspecified) 14
Pug 14
Terrier - Yorkshire 13
Shepherd Dog - German 12
Boxer (German Boxer) 12

Most Reported Reactions

Vomiting 163
Diarrhoea 61
Lethargy (see also Central nervous system depression in 'Neurological') 54
Facial swelling (see also 'Skin') 46
Other abnormal test result NOS 43
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 41
Anaphylaxis 39
Death 32
Lethargy (see also Central nervous system depression in Neurological) 32
Pale mucous membrane 29
Not eating 29
Facial swelling (see also Skin) 22

Outcome Breakdown

Recovered/Normal
177 (39.9%)
Outcome Unknown
148 (33.3%)
Ongoing
77 (17.3%)
Died
35 (7.9%)
Euthanized
7 (1.6%)

Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus: high report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

  • Compare Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine, Modified Live Virus (#330 of 2,679 by report volume); death-coded 9.5%. PlainBreed drug row · report volume stamp 443 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →